Cargando…
Identification of new EphA4 inhibitors by virtual screening of FDA-approved drugs
The receptor tyrosine kinase, erythropoietin-producing hepatocellular A4 (EphA4), was recently identified as a molecular target for Alzheimer’s disease (AD). We found that blockade of the interaction of the receptor and its ligands, ephrins, alleviates the disease phenotype in an AD transgenic mouse...
Autores principales: | Gu, Shuo, Fu, Wing-Yu, Fu, Amy K. Y., Tong, Estella Pui Sze, Ip, Fanny C. F., Huang, Xuhui, Ip, Nancy Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943255/ https://www.ncbi.nlm.nih.gov/pubmed/29743517 http://dx.doi.org/10.1038/s41598-018-25790-1 |
Ejemplares similares
-
α-Syntrophin regulates ARMS localization at the neuromuscular junction and enhances EphA4 signaling in an ARMS-dependent manner
por: Luo, Shuo, et al.
Publicado: (2005) -
EphA5 and EphA6: regulation of neuronal and spine morphology
por: Das, Gitanjali, et al.
Publicado: (2016) -
Ephrin Receptors (Eph): EphA1, EphA5, and EphA7 Expression in Uveal Melanoma—Associations with Clinical Parameters and Patient Survival
por: Gajdzis, Malgorzata, et al.
Publicado: (2020) -
Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors
por: Hatano, Manabu, et al.
Publicado: (2004) -
Targeting EphA2 in cancer
por: Xiao, Ta, et al.
Publicado: (2020)